Actively Recruiting
Shared Decision-Making Tool to Improve Treatment Conversations for Non-Small Cell Lung Cancer Patients
Led by Mayo Clinic · Updated on 2026-03-10
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a shared decision-making communication tool to improve the quality of discussions between patients with non-small cell lung cancer (NSCLC) and their clinicians. The study aims to see if using this tool during clinical visits enhances the decision-making process and reduces patients' doubts about their treatment choices compared to standard care alone. The trial focuses on adult NSCLC patients eligible for adjuvant treatment, highlighting the importance of patient involvement in choosing their care. Participants are randomly assigned to one of two groups: one group receives standard care visits with their clinician, while the other group receives standard care plus the use of the shared decision-making conversation tool during the visit. After these clinical encounters, patients are followed up at 2 and 6 weeks to assess the impact of the tool. Additional study activities include reviews of electronic health records and collecting surveys, video, and audio recordings as part of ancillary studies. During the study, researchers measure how well the shared decision-making process is implemented immediately after appointments and again at 2 weeks. They also assess how involved patients feel in decisions and gather feedback from clinicians about using the conversation tool after each encounter. The total participation involves the initial clinical visit plus follow-ups at two time points to monitor outcomes related to decision quality and satisfaction.
CONDITIONS
Brief Title
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Diagnosed with non-small cell lung cancer stage higher than 1B
- Eligible for adjuvant treatment as determined by their oncologist
- Have appointments at Mayo Clinic in Rochester
- Clinicians involved include MDs, DOs, fellows/residents, PAs, and NPs participating in identified departments
You will not qualify if you...
- Patients with major barriers to provide written informed consent or participate in shared decision-making, such as dementia or severe hearing or visual impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants attend a standard of care visit with their clinician, with or without the shared decision-making conversation tool depending on their assigned group.
1 visit (in-person)
Duration - 6 weeks
Participants are followed up to assess outcomes related to shared decision-making and decisional conflict after the treatment visit.
2 follow-up visits at 2 and 6 weeks post appointment
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here